Literature DB >> 26235928

Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction.

Gregory A Nichols1, Kristi Reynolds2, Teresa M Kimes3, A Gabriela Rosales3, Wing W Chan4.   

Abstract

Because heart failure (HF) with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) are different clinical entities with differing demographic characteristics, common HF outcomes may occur at different rates. Comparative outcome studies have been equivocal, and studies comparing resource utilization are scant. We used an observational cohort design to study 6,513 patients hospitalized for HF who had an EF measured during the hospitalization and were discharged alive within 30 days. We excluded 677 patients with borderline EF values (41% to 49%) and categorized the remaining as HFrEF (EF ≤40%, n = 2,205) and HFpEF (EF >50%, n = 3,631). Patients were followed for up to 1 year for all-cause re-hospitalization and mortality and annualized medical resource utilization. Patients with HFrEF and HFpEF experienced similar adjusted incidence rates of re-hospitalization, but those with HFrEF had a 39% increased risk of mortality at 30 days (rate ratio 1.39, 95% confidence interval 1.10 to 1.76) and 25% greater risk at 1 year (rate ratio1.25, 95% confidence interval 1.12 to 1.41). After adjustment for covariates, patients with HFpEF incurred significantly more annualized outpatient visits (21.5 vs 20.1, p = 0.002) and emergency room visits (3.24 vs 2.94, p = 0.002) than those with HFrEF, but absolute differences were small. High inpatient and pharmacy utilization did not differ. Our study suggests that whether a patient has HFrEF or HFpEF has little bearing on risk of re-hospitalization or inpatient resource utilization in the year after an HF hospitalization. Both groups experienced high mortality, but those with HFrEF had greater risk. In conclusion, from the standpoint of resource use, HF can be considered a single entity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26235928     DOI: 10.1016/j.amjcard.2015.07.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

Review 1.  Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.

Authors:  Christine Chow; Robert J Mentz; Stephen J Greene
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

Review 2.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

3.  Diastolic dysfunction evaluated by cardiac magnetic resonance: the value of the combined assessment of atrial and ventricular function.

Authors:  Giovanni Donato Aquaro; Fausto Pizzino; Anna Terrizzi; Scipione Carerj; Bijoy K Khandheria; Gianluca Di Bella
Journal:  Eur Radiol       Date:  2018-08-20       Impact factor: 5.315

4.  Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT.

Authors:  Bharathi Upadhya; James J Willard; Laura C Lovato; Michael V Rocco; Cora E Lewis; Suzanne Oparil; William C Cushman; Jeffrey T Bates; Natalie A Bello; Gerard Aurigemma; Karen C Johnson; Carlos J Rodriguez; Dominic S Raj; Anjay Rastogi; Leonardo Tamariz; Alan Wiggers; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2021-11-26       Impact factor: 8.790

5.  Comparison of Length of Stay, 30-Day Mortality, and 30-Day Readmission Rates in Medicare Patients With Heart Failure and With Reduced Versus Preserved Ejection Fraction.

Authors:  Matthew Shane Loop; Melissa K Van Dyke; Ligong Chen; Todd M Brown; Raegan W Durant; Monika M Safford; Emily B Levitan
Journal:  Am J Cardiol       Date:  2016-04-21       Impact factor: 2.778

6.  Population-based estimates of the burden of pneumonia hospitalizations in Hong Kong, 2011-2015.

Authors:  Xue Li; Joseph E Blais; Ian C K Wong; Anthony W Y Tam; Benjamin J Cowling; Ivan F N Hung; Esther W Y Chan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-25       Impact factor: 3.267

Review 7.  The Current Focus of Heart Failure Clinical Trials.

Authors:  Naga Venkata Pothineni; Ajoe John Kattoor; Swathi Kovelamudi; Satish Kenchaiah
Journal:  J Card Fail       Date:  2018-03-02       Impact factor: 5.712

Review 8.  Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review.

Authors:  Hannah Clark; Rezwanul Rana; Jeff Gow; Melissa Pearson; Tom van der Touw; Neil Smart
Journal:  Heart Fail Rev       Date:  2021-03-25       Impact factor: 4.214

9.  Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure.

Authors:  Chi Nguyen; Xian Zhang; Thomas Evers; Vincent J Willey; Hiangkiat Tan; Thomas P Power
Journal:  Am Health Drug Benefits       Date:  2020-09

Review 10.  Epigenetics in heart failure phenotypes.

Authors:  Alexander Berezin
Journal:  BBA Clin       Date:  2016-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.